Boston, MA, United States of America

Adnan Abu-Yousif

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adnan Abu-Yousif: Innovator in Bispecific Antibodies

Introduction

Adnan Abu-Yousif is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. His innovative work has the potential to advance therapeutic options for various diseases.

Latest Patents

Adnan holds a patent for "ANTI-C-MET tandem Fc bispecific antibodies." This patent describes tandem Fcs and tandem Fc antibodies (TFcAs), which include one or more binding sites that specifically target cell surface receptors. The binding sites are interconnected through a TFc, which consists of a first and a second Fc region linked by a TFc linker to form a contiguous polypeptide. This design allows for dimerization to create an Fc dimer. Notably, the exemplary TFcBAs developed by Adnan bind to the c-Met and EpCam receptors, effectively inhibiting signal transduction through these receptors.

Career Highlights

Adnan is currently employed at Merrimack Pharmaceuticals, Inc., where he continues to push the boundaries of antibody technology. His work is instrumental in the development of novel therapeutic strategies that leverage the unique properties of bispecific antibodies.

Collaborations

Adnan collaborates with esteemed colleagues such as Brian Harms and Neeraj Kohli. Their combined expertise fosters an environment of innovation and progress in the field of biopharmaceuticals.

Conclusion

Adnan Abu-Yousif is a key figure in the advancement of bispecific antibody technology, with a focus on innovative therapeutic solutions. His contributions are paving the way for new treatments that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…